Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

GlobeNewswire May 3, 2021

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA(TM) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

GlobeNewswire April 29, 2021

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

GlobeNewswire April 7, 2021

Cara Therapeutics Set to Join S&P SmallCap 600

PR Newswire April 5, 2021

Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021

GlobeNewswire March 31, 2021

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

GlobeNewswire March 30, 2021

Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA(TM)* injection in hemodialysis patients with moderate-to-severe pruritus

GlobeNewswire March 8, 2021

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA(TM)* injection in hemodialysis patients with moderate-to-severe pruritus

Business Wire March 8, 2021

Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 25, 2021

Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

GlobeNewswire February 18, 2021

This is Why Cannabis Stocks Could Reach New Highs in 2021

Livemoney February 4, 2021

Cara Initiates Phase 2 Trial of Oral KORSUVA(TM) for the Treatment of Pruritus in Patients with Notalgia Paresthetica

GlobeNewswire January 11, 2021

Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2021

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA(TM) Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

GlobeNewswire December 28, 2020

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics

PR Newswire December 24, 2020

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

GlobeNewswire December 22, 2020

Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA(TM) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

GlobeNewswire December 2, 2020

Cara Therapeutics to Present at Multiple Upcoming Investor Conferences

GlobeNewswire November 11, 2020

Cara Therapeutics Reports Third Quarter 2020 Financial Results

GlobeNewswire November 9, 2020

Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

GlobeNewswire November 2, 2020